Skip to main content
Top
Published in: Pediatric Drugs 2/2014

01-04-2014 | Current Opinion

Management of Hypercholesterolemia in Children

Authors: Marjet J. A. M. Braamskamp, Barbara A. Hutten, Albert Wiegman, John J. P. Kastelein

Published in: Pediatric Drugs | Issue 2/2014

Login to get access

Abstract

Cardiovascular disease (CVD) remains the leading cause of death and morbidity in our society. One of the major risk factors for CVD is hypercholesterolemia. Hypercholesterolemia in children can be caused by a hereditary disorder or can be secondary to other diseases or drugs. In order to prevent CVD later in life, children with hypercholesterolemia should be identified and treated as early as possible. Currently, several different screening strategies have been developed, using either universal screening or case finding to search for children at risk. Once those children are identified, the first step in treatment is lifestyle adjustment. If cholesterol levels remain elevated, the drugs of first choice are statins. Other pharmacological options are ezetimibe or bile acid sequestrants. These agents have all proven to be safe and effective in lowering low-density lipoprotein cholesterol levels and improving surrogate markers of CVD. However, there is a need for long-term follow-up studies to answer the question as to whether it is safe to initiate treatment at a young age to prevent CVD later in life.
Literature
1.
go back to reference McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;17(216):1185–7.CrossRef McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. JAMA. 1971;17(216):1185–7.CrossRef
2.
go back to reference Berenson G, Srinivasan S. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650–6.PubMedCrossRef Berenson G, Srinivasan S. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650–6.PubMedCrossRef
3.
go back to reference Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018–24. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. JAMA. 1990;264:3018–24.
4.
go back to reference Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;31(363):369–70.CrossRef Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;31(363):369–70.CrossRef
5.
go back to reference De Jongh S, Lilien MR, op’t Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21. De Jongh S, Lilien MR, op’t Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21.
6.
go back to reference Goldstein JL, Hobbs HH, Brown MS. Part 12: Lipids chapter 120: familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2863–913. Goldstein JL, Hobbs HH, Brown MS. Part 12: Lipids chapter 120: familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 2863–913.
7.
go back to reference Innerarity TL, Weisgraber KH, Arnold KAYS, Mahley RW, Kraussf RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84:6919–23. Innerarity TL, Weisgraber KH, Arnold KAYS, Mahley RW, Kraussf RM, Vega GL, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA. 1987;84:6919–23.
8.
go back to reference Abifadel M, Rabès J-P, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520–9.PubMedCrossRef Abifadel M, Rabès J-P, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520–9.PubMedCrossRef
9.
go back to reference Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci. 2011;48:1–18.PubMedCrossRef Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci. 2011;48:1–18.PubMedCrossRef
10.
go back to reference Goldstein JL, Schrott HG, Bierman EL. Hyperlipidemia in coronary heart disease and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.PubMedCentralPubMedCrossRef Goldstein JL, Schrott HG, Bierman EL. Hyperlipidemia in coronary heart disease and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52:1544–68.PubMedCentralPubMedCrossRef
11.
go back to reference Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;1(49):476–88.CrossRef Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;1(49):476–88.CrossRef
12.
go back to reference Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet. 2012;379:1330. Macchiaiolo M, Gagliardi MG, Toscano A, Guccione P, Bartuli A. Homozygous familial hypercholesterolaemia. Lancet. 2012;379:1330.
13.
go back to reference Veerkamp MJ. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;1(22):274–82.CrossRef Veerkamp MJ. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;1(22):274–82.CrossRef
14.
go back to reference Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27–33.CrossRef Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27–33.CrossRef
15.
go back to reference Gaddi A, Cicero a FG, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877–86. Gaddi A, Cicero a FG, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3:877–86.
16.
go back to reference De Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998;9:189–96.PubMedCrossRef De Graaf J, Stalenhoef AF. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr Opin Lipidol. 1998;9:189–96.PubMedCrossRef
17.
go back to reference Li S, Chen W, Srinivasan SR, Xu J, Berenson GS. Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol. 2012;1(176 Suppl):S142–9.CrossRef Li S, Chen W, Srinivasan SR, Xu J, Berenson GS. Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol. 2012;1(176 Suppl):S142–9.CrossRef
18.
go back to reference Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003;1(23):1963–70.CrossRef Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2003;1(23):1963–70.CrossRef
19.
go back to reference Lütjohann D, von Bergmann K. Phytosterolaemia: diagnosis, characterization and therapeutical approaches. Ann Med. 1997;29:181–4.PubMedCrossRef Lütjohann D, von Bergmann K. Phytosterolaemia: diagnosis, characterization and therapeutical approaches. Ann Med. 1997;29:181–4.PubMedCrossRef
20.
go back to reference Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;3(350):2362–74.CrossRef Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;3(350):2362–74.CrossRef
21.
go back to reference Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97:272–6.PubMedCrossRef Kusters DM, de Beaufort C, Widhalm K, Guardamagna O, Bratina N, Ose L, et al. Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child. 2012;97:272–6.PubMedCrossRef
22.
go back to reference Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221–63.PubMedCrossRef Watts GF, Sullivan DR, Poplawski N, van Bockxmeer F, Hamilton-Craig I, Clifton PM, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler Suppl. 2011;12:221–63.PubMedCrossRef
23.
go back to reference Griffin TC, Christoffel KK, Binns HJ, McGuire PA. Family history evaluation as a predictive screen for childhood hypercholesterolemia, Pediatric Practice Research Group. Pediatrics. 1989;84:365–73.PubMed Griffin TC, Christoffel KK, Binns HJ, McGuire PA. Family history evaluation as a predictive screen for childhood hypercholesterolemia, Pediatric Practice Research Group. Pediatrics. 1989;84:365–73.PubMed
24.
go back to reference Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet. 2001;357:165–8. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet. 2001;357:165–8.
25.
go back to reference Huijgen R, Kindt I, Verhoeven SBJ, Sijbrands EJG, Vissers MN, Kastelein JJP, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.PubMedCentralPubMedCrossRef Huijgen R, Kindt I, Verhoeven SBJ, Sijbrands EJG, Vissers MN, Kastelein JJP, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.PubMedCentralPubMedCrossRef
26.
go back to reference Avis HJ, Kusters DM, Vissers MN, Huijgen R, Janssen TH, Wiegman A, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr. 2012;161:99–103.PubMedCrossRef Avis HJ, Kusters DM, Vissers MN, Huijgen R, Janssen TH, Wiegman A, et al. Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr. 2012;161:99–103.PubMedCrossRef
27.
go back to reference Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl):S213–56. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl):S213–56.
28.
go back to reference Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189–214.PubMedCrossRef Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007;120:e189–214.PubMedCrossRef
29.
go back to reference Schroeder AR, Redberg RF. Cholesterol screening and management in children and young adults should start early—no! Clin Cardiol. 2012;35:665–8.PubMedCrossRef Schroeder AR, Redberg RF. Cholesterol screening and management in children and young adults should start early—no! Clin Cardiol. 2012;35:665–8.PubMedCrossRef
30.
go back to reference Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307:259–60. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307:259–60.
31.
go back to reference Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;18(307):257–8. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;18(307):257–8.
32.
go back to reference Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;22(335):599.CrossRef Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ. 2007;22(335):599.CrossRef
33.
go back to reference Friedman LA, Morrison J a, Daniels SR, McCarthy WF, Sprecher DL. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics. 2006;118:165–72. Friedman LA, Morrison J a, Daniels SR, McCarthy WF, Sprecher DL. Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study. Pediatrics. 2006;118:165–72.
34.
go back to reference Obarzanek E, Kimm SYS, Barton BA, Van Horn L, Kwiterovich Jr PO, Simons-Morton DG, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64. Obarzanek E, Kimm SYS, Barton BA, Van Horn L, Kwiterovich Jr PO, Simons-Morton DG, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64.
35.
go back to reference Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;28(116):1032–40.CrossRef Niinikoski H, Lagström H, Jokinen E, Siltala M, Rönnemaa T, Viikari J, et al. Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;28(116):1032–40.CrossRef
36.
go back to reference Pahkala K, Heinonen OJ, Simell O, Viikari JS, Rönnemaa T, Niinikoski H, et al. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation. 2011;124:1956–63. Pahkala K, Heinonen OJ, Simell O, Viikari JS, Rönnemaa T, Niinikoski H, et al. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation. 2011;124:1956–63.
37.
go back to reference Pahkala K, Heinonen OJ, Lagström H, Hakala P, Hakanen M, Hernelahti M, et al. Clustered metabolic risk and leisure-time physical activity in adolescents: effect of dose? Br J Sports Med. 2012;46:131–7.PubMedCrossRef Pahkala K, Heinonen OJ, Lagström H, Hakala P, Hakanen M, Hernelahti M, et al. Clustered metabolic risk and leisure-time physical activity in adolescents: effect of dose? Br J Sports Med. 2012;46:131–7.PubMedCrossRef
38.
go back to reference Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009;205:23–32.PubMedCrossRef Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009;205:23–32.PubMedCrossRef
39.
go back to reference Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;8(366):1267–78. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;8(366):1267–78.
40.
go back to reference Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DCG, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337:a2423.
41.
go back to reference Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJP, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007;27:1803–10.
42.
go back to reference Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;16(72):773–88.CrossRef Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;16(72):773–88.CrossRef
43.
go back to reference Kusters DM, Lahsinoui HH, van de Post JAM, Wiegman A, Wijburg FA, Kastelein JJP, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2012;10:363–78.PubMedCrossRef Kusters DM, Lahsinoui HH, van de Post JAM, Wiegman A, Wijburg FA, Kastelein JJP, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther. 2012;10:363–78.PubMedCrossRef
44.
go back to reference Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg a SP, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg a SP, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664–8.
45.
go back to reference West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet. 1980;25(2):873–5.CrossRef West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet. 1980;25(2):873–5.CrossRef
46.
go back to reference Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatr Drugs. 2010;1(12):133–40.CrossRef Perry CM. Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. Paediatr Drugs. 2010;1(12):133–40.CrossRef
47.
go back to reference Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231–6.e1–3. Stein EA, Marais AD, Szamosi T, Raal FJ, Schurr D, Urbina EM, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr. 2010;156:231–6.e1–3.
48.
go back to reference Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;15(90):1092–7.CrossRef Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;15(90):1092–7.CrossRef
49.
go back to reference Knopp R. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–41.PubMedCrossRef Knopp R. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–41.PubMedCrossRef
50.
go back to reference Clauss S, Wai K-M, Kavey R-EW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869–72.PubMedCrossRef Clauss S, Wai K-M, Kavey R-EW, Kuehl K. Ezetimibe treatment of pediatric patients with hypercholesterolemia. J Pediatr. 2009;154:869–72.PubMedCrossRef
51.
go back to reference Van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;21(52):1421–9.CrossRef Van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;21(52):1421–9.CrossRef
52.
go back to reference Pijlman AH, Huijgen R, Verhagen SN, Imholz BPM, Liem AH, Kastelein JJP, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189–94. Pijlman AH, Huijgen R, Verhagen SN, Imholz BPM, Liem AH, Kastelein JJP, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189–94.
53.
go back to reference Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29–36.
54.
go back to reference Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891–900.
55.
go back to reference Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998–1006.
56.
go back to reference McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.PubMedCentralPubMedCrossRef McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.PubMedCentralPubMedCrossRef
57.
go back to reference Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40–6.
58.
59.
go back to reference Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19–27. Stefanutti C, Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl. 2013;14:19–27.
60.
go back to reference Palcoux J-B, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger J-L, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12:195–201.PubMedCrossRef Palcoux J-B, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger J-L, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial. 2008;12:195–201.PubMedCrossRef
61.
go back to reference Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331–9.PubMedCrossRef Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331–9.PubMedCrossRef
Metadata
Title
Management of Hypercholesterolemia in Children
Authors
Marjet J. A. M. Braamskamp
Barbara A. Hutten
Albert Wiegman
John J. P. Kastelein
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 2/2014
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-013-0060-2

Other articles of this Issue 2/2014

Pediatric Drugs 2/2014 Go to the issue